{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:55:37Z","timestamp":1780581337980,"version":"3.54.1"},"reference-count":105,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1517\/14740338.2011.582037","type":"journal-article","created":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T09:07:55Z","timestamp":1304586475000},"page":"839-850","source":"Crossref","is-referenced-by-count":30,"title":["Adverse reactions to duloxetine in depression"],"prefix":"10.1517","volume":"10","author":[{"given":"Istvan","family":"Bitter","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Filipovits","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Czobor","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy","place":["Hungary"]},{"name":"Nathan S. Kline Institute for Psychiatric Research","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,5,5]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-19"},{"key":"e_1_3_1_3_1","article-title":"Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis","author":"Oestergaard S","year":"2010","unstructured":"Oestergaard S, Moldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis. J Affect Disord 2010;published online 13 October 2010, doi:S0165-0327(10)00548-3","journal-title":"J Affect Disord"},{"issue":"2","key":"e_1_3_1_4_1","first-page":"CD006532","article-title":"Escitalopram versus other antidepressive agents for depression","author":"Cipriani A","year":"2009","unstructured":"Cipriani A, Santilli C, Furukawa TA, Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;(2):CD006532","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60046-5"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318930-000000000-00000"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-10-200811180-00007"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9104su1c.01"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050006"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003747441"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464220-00005"},{"key":"e_1_3_1_12_1","unstructured":"Yentreve: European Public Assessment Reports - Product Information. European Medicines Agency. Last updated: 10 February 2011. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000545\/human_med_001164.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=true. [Last accessed 15 February 2011]"},{"key":"e_1_3_1_13_1","unstructured":"FDA clears Cymbalta to treat chronic musculoskeletal pain. FDA News Release. 2010.11.04. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm232708.htm. Last accessed 8 February 2011"},{"key":"e_1_3_1_14_1","unstructured":"Cymbalta - Highlights of Prescribing Information. FDA Approved Drug Products. 2009.11.19. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021427s030lbl.pdf. Last accessed 8 February 2011"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1213"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902806431"},{"key":"e_1_3_1_17_1","article-title":"Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics","author":"Gao K","year":"2010","unstructured":"Gao K, Kemp DE, Fein E, Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2010;published online 19 October 2010, doi:10.4088\/JCP.09r05535gre","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.6.987"},{"key":"e_1_3_1_19_1","unstructured":"Cymbalta: European Public Assessment Reports - Product Information. European Medicines Agency. Last updated: 10 February 2011. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000572\/WC500036781.pdf. Last accessed 12 February 2011"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900019726"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.08.010"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847030-00005"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.2.215"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.28"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000341891.43501.6b"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-7-43"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.188.4.346"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.696"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X162719"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1634"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07030454"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246216.26400.db"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.12.049"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000237950.65517.be"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.02.017"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2005.08.010"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0905"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1015"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20339"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.12.1443"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.024"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2005.08.006"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E084"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02374.x"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0407"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2006.03.004"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000132448.65972.d9"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.01.002"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v05n0105"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v08n0404"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0309"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2007.01.008"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32807fb1b2"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04592"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00006"},{"key":"e_1_3_1_56_1","unstructured":"Cymbalta (Duloxetine Hydrochloride) - Warnings and Precautions. DrugLib.com Drug Information Portal. 2009.02.16. Available from: http:\/\/www.druglib.com\/druginfo\/cymbalta\/warnings_precautions. [Last accessed 9 April 2011]"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.04.018"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.3.281"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s2820"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.S32193"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000155815.44338.95"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01260.x"},{"issue":"3","key":"e_1_3_1_63_1","first-page":"5","article-title":"Recognition and assessment of sexual dysfunction associated with depression","volume":"62","author":"Clayton AH","year":"2001","unstructured":"Clayton AH. Recognition and assessment of sexual dysfunction associated with depression. J Clin Psychiatry 2001;62Suppl 3:5-9","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/00926239708403923"},{"issue":"3","key":"e_1_3_1_65_1","first-page":"10","article-title":"Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction","volume":"62","author":"Montejo AL","year":"2001","unstructured":"Montejo AL, Llorca G, Izquierdo JA, Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62Suppl 3:10-21","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a5233f"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0603"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.02113.x"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093586"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e318160738e"},{"issue":"6","key":"e_1_3_1_71_1","first-page":"33","article-title":"Major depressive disorder, antidepressants, and sexual dysfunction","volume":"67","author":"Clayton AH","year":"2006","unstructured":"Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67Suppl 6:33-7","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.00880.x"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-4-11"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.1.157"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.4.523"},{"key":"e_1_3_1_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f41d7e"},{"key":"e_1_3_1_77_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1110"},{"key":"e_1_3_1_78_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S4358"},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000080708.87092.cc"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319200-000000000-00000"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.09.003"},{"key":"e_1_3_1_82_1","first-page":"437","article-title":"Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy","volume":"98","author":"Bailey RK","year":"2006","unstructured":"Bailey RK, Mallinckrodt CH, Wohlreich MM, Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006;98:437-47","journal-title":"J Natl Med Assoc"},{"key":"e_1_3_1_83_1","first-page":"67","article-title":"Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients","author":"Lewis-Fernandez R","year":"2006","unstructured":"Lewis-Fernandez R, Blanco C, Mallinckrodt CH, Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. J Clin Psychiatry 2006;67-1379-90","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746090-00004"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2007.01666.x"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.04.006"},{"key":"e_1_3_1_87_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.6.900"},{"key":"e_1_3_1_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200503000-00008"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01476.x"},{"key":"e_1_3_1_90_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847020-00003"},{"key":"e_1_3_1_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-006-0553-4"},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0042"},{"key":"e_1_3_1_93_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.1764"},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0071"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.4.546"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M317"},{"key":"e_1_3_1_97_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07071194"},{"key":"e_1_3_1_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200502243520822"},{"key":"e_1_3_1_99_1","first-page":"e66","article-title":"Adverse effects in neonates exposed to SSRIs and SNRI in late gestation--Motherisk Update 2008","volume":"16","author":"Koren G","year":"2009","unstructured":"Koren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation--Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e66-7","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_1_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.009"},{"key":"e_1_3_1_101_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1103296"},{"key":"e_1_3_1_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31815ac4d2"},{"key":"e_1_3_1_103_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528020-00005"},{"key":"e_1_3_1_104_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701586331"},{"key":"e_1_3_1_105_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990484"},{"key":"e_1_3_1_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jflm.2010.02.002"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14740338.2011.582037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:45:43Z","timestamp":1770889543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14740338.2011.582037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,5]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1517\/14740338.2011.582037"],"URL":"https:\/\/doi.org\/10.1517\/14740338.2011.582037","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,5]]}}}